AbbVie的投资者尽管损失了收入,却在AbbVie的股权上起推波助澜作用。 Investors boost stakes in AbbVie, despite missed earnings, earning a "Moderate Buy" rating.

全球投资控股公司和其他机构投资者增加了对AbbVie公司的股份,AbbVie公司是一家制药公司,以Humira等药物著称。 Allspring Global Investments Holdings LLC and other institutional investors have increased their stakes in AbbVie Inc., a pharmaceutical company known for drugs like Humira. 尽管缺少收入估计, AbbVie还是从分析家那里获得了“移动买家”的评级, 协商一致的目标价格为208.35美元。 Despite missing earnings estimates, AbbVie has received a "Moderate Buy" rating from analysts with a consensus target price of $208.35. 该公司的市场上限为3 411.6亿美元,物价对收益比率为80.44。 The company has a market cap of $341.16 billion and a price-to-earnings ratio of 80.44.